Article Data

  • Views 393
  • Dowloads 119

Original Research

Open Access

Endometrial adenocarcinoma in young-aged women: a Turkish population study

  • T. Gungor1
  • N. Cetinkaya2,*,
  • B. Ozdal2
  • H. Yalcin2
  • S. Erkaya3
  • H.I. Yakut4

1Hitit University Medical Faculty, Department of Obstetrics and Gynecologic Oncology, Corum, Turkey

2Zekai Tahir Burak Women’s Health Education and Research Hospital, Department of Gynecologic Oncology, Ankara, Turkey

3Zekai Tahir Burak Women’s Health Education and Research Hospital, Department of Obstetrics and Gynecology, Ankara, Turkey

4Zekai Tahir Burak Women’s Health Education and Research Hospital, Department of Pediatrics, Ankara, Turkey

DOI: 10.12892/ejgo2712.2015 Vol.36,Issue 6,December 2015 pp.667-671

Published: 10 December 2015

*Corresponding Author(s): N. Cetinkaya E-mail: cetinkayanilufer@gmail.com

Abstract

Purpose of investigation: The present study aims to investigate the incidence, clinicopathological features, and experience of treatment outcomes of patients with endometrial adenocarcinoma (EC) at ≤ 40 years of age in a gynecologic oncology reference center in Ankara, Turkey. Materials and Methods: This retrospective study included 577 patients with EC, diagnosed and treated between 2007 and 2013. Results: The incidence of EC ≤ 40 years of age was 5.1% (n: 30). The mean age at diagnosis was 35.5 (range: 27-40). Most of the patients with EC were overweight or obese. However, 23% had normal body mass index (BMI). Infertility was seen as a risk factor in 38.4%. The mean duration of postoperative follow-up was 38.3 months with rates of disease persistence and recurrence 14.2% and 28.5%, respectively. Conclusion: The disease is diagnosed usually in its early stage and has a good prognosis. Appropriately selected patients with fertility desire have the opportunity to conceive with conservative management.

Keywords

Endometrial adenocarcinoma; Gynecological cancer; Young women; Infertility; Obesity.

Cite and Share

T. Gungor,N. Cetinkaya,B. Ozdal,H. Yalcin,S. Erkaya,H.I. Yakut. Endometrial adenocarcinoma in young-aged women: a Turkish population study. European Journal of Gynaecological Oncology. 2015. 36(6);667-671.

References

[1] Crissman J.D., Azoury R.S., Barnes A.E., Schellhas H.F.: “En-dometrial carcinoma in women 40 years of age or younger”. Obstet. Gynecol., 1981, 57, 699.

[2] Gallup D.G., Stock R.J.: “Adenocarcinoma of the endometrium in women 40 years of age or younger”. Obstet. Gynecol., 1984, 64, 417.

[3] Iram S., Musonda P., Ewies A.A.: “Premenopausal bleeding: When should the endometrium be investigated? A retrospective non-comparative study of 3006 women”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2010, 148, 86.

[4] Pellerin G.P., Finan M.A.: “Endometrial cancer in women 45 years of age or younger: a clinicopathological analysis”. Am. J. Obstet. Gynecol., 2005, 193, 1640.

[5] Kaku T., Matsuo K., Tsukamoto N., Shimamoto T., Sugihara K., Tsu-ruchi N., et al.: “Endometrial carcinoma in women aged 40 years or younger: a Japanese experience”. Int. J. Gynecol. Cancer, 1993, 3, 147.

[6] Spencer C.P., Whitehead M.I.: “Endometrial assessment revisited”. Br. J. Obstet. Gynaecol., 1999, 106, 623.

[7] Bayer S.R., DeCherney A.H.: “Clinical manifestations and treatment of dysfunctional uterine bleeding”. JAMA, 1993, 269, 1823.

[8] Creasman W.: “Revised FIGO staging for carcinoma of the endometrium”. Int. J. Gynaecol. Obstet., 2009, 105, 109.

[9] Dizon D.S.: “Treatment options for advanced endometrial carcinoma”. Gynecol. Oncol., 2010, 117, 373.

[10] Gunderson C.C., Fader A.N., Carson K.A., Bristow R.E.: “Onco-logic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review”. Gynecol. Oncol., 2012, 125, 477.

[11] Vehid S., Aran S.N., Koksal S., Isiloglu H., Senocak M.: “The preva-lence and the age at the onset of menopause in Turkish women in rural area”. Saudi Med. J., 2006, 27, 1381.

[12] Duijkers I.J., Klipping C.: “Polycystic ovaries, as defined by the 2003 Rotterdam consensus criteria, are found to be very common in young healthy women”. Gynecol. Endocrinol., 2010, 26, 152.

[13] Soliman P.T., Oh J.C., Schmeler K.M., Sun C.C., Slomovitz B.M., Gershenson D.M., et al.: “Risk factors for young premenopausal women with endometrial cancer”. Obstet. Gynecol., 2005, 105, 575.

[14] Koss L.G., Schreiber K., Oberlander S.G., Moussouris H.F., Lesser M.: “Detection of endometrial carcinoma and hyperplasia in asymp-tomatic women”. Obstet. Gynecol., 1984, 64, 1.

[15] Bean S.M., Connolly K., Roberson J., Eltoum I., Chhieng D.C.: “In-cidence and clinical significance of morphologically benign-ap-pearing endometrial cells in patients age 40 years or older: the impact of the 2001 Bethesda System”. Cancer, 2006, 108, 39.

[16] Beal H.N., Stone J., Beckmann M.J., McAsey M.E.: “Endometrial cells identified in cervical cytology in women > or = 40 years of age: criteria for appropriate endometrial evaluation”. Am. J. Obstet. Gynecol., 2007, 196, 568.

[17] Werner H.M., Trovik J., Marcickiewicz J., Tingulstad S., Staff A.C., Engh M.E., et al.: “A discordant histological risk classification in preoperative and operative biopsy in endometrial cancer is reflected in metastatic risk and prognosis”. Eur. J. Cancer, 2013, 49, 625.

[18] Yildiz A., Yetimalar H., Kasap B., Aydin C., Tatar S., Soylu F., et al.: “Preoperative serum CA 125 level in the prediction of the stage of disease in endometrial carcinoma”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2012, 164, 191.

[19] Onat G., Kizilkaya Beji N.: “Effects of infertility on gender differences in marital relationship and quality of life: a case-control study of Turkish couples”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2012, 165, 243.

[20] Dursun P., Erkanli S., Guzel A.B., Gultekin M., Tarhan N.C., Al-tundag O., et al.: “A Turkish Gynecologic Oncology Group study of fertility-sparing treatment for early-stage endometrial cancer”. Int. J. Gynaecol. Obstet., 2012, 119, 270.

[21] Perri T., Korach J., Gotlieb W.H., Beiner M., Meirow D., Friedman E., et al.: “Prolonged conservative treatment of endometrial cancer patients: more than 1 pregnancy can be achieved”. Int. J. Gynecol. Cancer, 2011, 21, 72.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top